002773.SZChengdu Kanghong Pharmaceutical Group Co., Ltd
The schedule
- Wed28Oct
The Q3 2026 financial report will detail sequential revenue recovery and the impact of SG&A optimization on the bottom line, anchoring at an expected $19.51.
- Tue15Dec
China's National Healthcare Security Administration (NHSA) will announce the updated National Reimbursement Drug List (NRDL), evaluating Conbercept pricing from a $21.80 anchor.
- Thu22Apr
Full-year 2026 results will be published alongside the annual dividend declaration and initial fiscal 2027 forward guidance, starting from a baseline of $18.50.
- Tue15Jun
Expected interim safety and efficacy update from the Phase 1 clinical trial of KH921, the company's novel AAV gene therapy product, tracking from a $21.50 starting price.
Resolved
- Wed26Aug
MIXED · $20.31 at outcome
Price at outcome date was between bear floor ($19.51) and bull target ($23.55).
Chengdu Kanghong is scheduled to release its H1 2026 earnings on August 26, revealing the latest sales trajectory for Conbercept and other core generics from the $21.11 base price.